We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Combination Laser Platform Treats Glaucoma and Cataract

By HospiMedica International staff writers
Posted on 22 Jul 2014
Print article
Image: The Optimis Fusion integrated laser platform (Photo courtesy of Quantel Medical).
Image: The Optimis Fusion integrated laser platform (Photo courtesy of Quantel Medical).
An integrated laser offers ophthalmologists a versatile armamentarium for treating both cataract and glaucoma in an efficient combination platform.

The Optimis Fusion integrated laser combines advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional yttrium aluminium garnet (YAG) photodisruption to provide a platform for managing glaucoma and lowering intraocular pressure. The SLT therapy works by targeting melanin-rich cells that absorb the laser energy to induce a healing response, improving the function of the trabecular meshwork. Laser energy is delivered in short, fixed pulses over a large, homogeneous spot size, resulting in no thermal damage to the trabecular meshwork, making it a repeatable procedure.

The YAG mode delivers high-performance photodisruption for capsulotomy and peripheral iridotomy surgical procedures. The gaussian laser beam profile allows for precise laser delivery at minimum energy levels, avoiding adverse side effects such as lens pitting. Precise tissue targeting is achieved with the advanced two-point aiming beam, allowing for fast and accurate targeting of the capsule, and an adjustable anterior and posterior offset feature for easy focus adjustment in front of, behind, or at the point of disruption. The Optimis Fusion integrated laser is a product of Quantel Medical (Clermont-Ferrand, France).

“We are extremely excited to bring our breakthrough laser platform to the US market,” said Jean-Marc Gendre, CEO of Quantel Medical. “The Optimis Fusion has proven to be a very attractive laser platform since introduction earlier this year in other markets. Driving the acceptance of this product introduction is the ability to combine a 532 nm monospot or multispot retina laser, a unique feature to Quantel's laser line.”

Related Links:
Quantel Medical


Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Wireless Handheld Ultrasound System
TE Air

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.